Current Headlines

  1. New Research-Based Pharmaceutical Industry Report Provides Insights On How To Slow Down Antimicrobial Resistance (AMR) And Boost Antibiotic R&D
    4/29/2015

    The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) released recently a new report on antimicrobial resistance (AMR) calling for a global coordinated, multi-faceted policy approach to minimize the growth of resistance, highlighting the scientific challenges associated with the development of new antibiotics and the need for economic incentives to ensure sustainable investments in antibacterial research and development.

  2. AVT And Global Vision Collaborate To Offer Cutting-Edge Offline Inspection Solutions For Printing Industry
    4/29/2015

    AVT, the world leader in print inspection, print process control, and quality assurance, is joining forces with leading proofing solutions provider Global Vision to offer advanced offline inspection solutions to the worldwide printing market.

  3. Standard Clinical Assays Can Obscure The Diversity Of Breast Cancer Subtypes
    4/24/2015

    Classification systems that categorize breast cancers based on estrogen receptor (ER), progesterone receptor (PR), and HER2 expression levels may obscure the heterogeneity of other key tumor features, according to a new study published in The Oncologist on April 23, 2015.

  4. BioReliance Licenses B-CLEAR® Technology From Qualyst Transporter Solutions For Drug Transporter Studies
    4/21/2015

    BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation's (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial (www.sigmaaldrich.com/safc), is pleased to announce a non-exclusive license agreement with Qualyst Transporter Solutions (QTS) for its proprietary B-CLEAR® technology. Used in conjunction with BioReliance technologies, B-CLEAR enables researchers to assess drug disposition and drug interactions within complex, whole-cell liver systems.

  5. BioOutsource Ltd. Acquired By Sartorius Stedim Biotech
    4/17/2015

    BioOutsource Ltd.(BioOutsource), a leading provider of contract testing services for the biopharmaceutical industry, has been acquired by Sartorius Stedim Biotech(SSB), a leading international supplier for the biopharmaceutical industries.

  6. Genomic Profiling Of Gastric Cancer Identifies Drug-Targetable Mutations
    4/16/2015

    The majority of gastric cancers harbor genomic alterations (GAs) associated with potential benefit from targeted therapies, according to a new study published in The Oncologist on April 16, 2015.

  7. Multichannel Pipette Accelerates Sample Screening And Genotyping Assays
    4/15/2015

    INTEGRA has published a new customer video* from the Institute of Clinical Chemistry research group at the Technical University of Munich (TUM), in which researcher Christina Thomas reviews how the VOYAGER multichannel pipette has accelerated their sample screening and genotyping assays.

  8. Sartorius Stedim Biotech Launches A New Single-Use Harvesting Technology For High Cell Density Cultures Up To 2,000 L
    4/14/2015

    Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has introduced Sartoclear Dynamics®, a clarification system featuring new single-use technology for harvesting mammalian cell cultures with high cell densities.

  9. Rentschler Biotechnologie Expands European Manufacturing Capabilities With GE Healthcare Life Sciences Bioprocess Technologies
    4/14/2015

    GE Healthcare Life Sciences a provider of tools, technologies and services to the biopharmaceutical manufacturing industry and Rentschler Biotechnologie GmbH, a leading contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced recently a joint celebration to mark the handover of GE Healthcare’s 1000th ÄKTAprocess and the expansion of Rentschler’s biopharmaceutical manufacturing capabilities in Laupheim, Germany.

  10. New Pre-Validated Fluorinated Fragment Library Boosts Drug Screening Efficiency
    4/14/2015

    Researchers engaged in drug discovery can now benefit from a new library of fluorinated compounds with superior drug-like characteristics designed to maximize the efficiency of fluorine Nuclear Magnetic Resonance (NMR) and X-ray crystallography screening, saving both time and cost in the process.

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.